265 related articles for article (PubMed ID: 34538541)
21. Elexacaftor-tezacaftor-ivacaftor overdose in an adolescent female with cystic fibrosis.
Lyman BC; Seay J; Contreary C; Savant AP; Dell ML; Hescock GC
Pediatr Pulmonol; 2022 Dec; 57(12):3174-3176. PubMed ID: 35962539
[No Abstract] [Full Text] [Related]
22. Ethical Dilemma: Elexacaftor-Tezacaftor-Ivacaftor or Lung Transplantation in Cystic Fibrosis and End-Stage Lung Disease?
Breuer O; Shoseyov D; Koretz S; Alyan N; Reiter J; Cohen-Cymberknoh M; Wexler I; Kerem E
Chest; 2022 Mar; 161(3):773-780. PubMed ID: 34506793
[TBL] [Abstract][Full Text] [Related]
23. Influence of highly effective modulator therapy on the sputum proteome in cystic fibrosis.
Maher RE; Barry PJ; Emmott E; Jones AM; Lin L; McNamara PS; Smith JA; Lord RW
J Cyst Fibros; 2024 Mar; 23(2):269-277. PubMed ID: 37951788
[TBL] [Abstract][Full Text] [Related]
24. The march towards CFTR modulator access for all people with CF: The end of the beginning.
VanDevanter DR
J Cyst Fibros; 2021 Mar; 20(2):185-187. PubMed ID: 33495080
[No Abstract] [Full Text] [Related]
25. Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More
Griese M; Costa S; Linnemann RW; Mall MA; McKone EF; Polineni D; Quon BS; Ringshausen FC; Taylor-Cousar JL; Withers NJ; Moskowitz SM; Daines CL
Am J Respir Crit Care Med; 2021 Feb; 203(3):381-385. PubMed ID: 32969708
[No Abstract] [Full Text] [Related]
26. Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations.
Munck A; Kerem E; Ellemunter H; Campbell D; Wang LT; Ahluwalia N; Owen CA; Wainwright C
J Cyst Fibros; 2020 Nov; 19(6):962-968. PubMed ID: 32546431
[TBL] [Abstract][Full Text] [Related]
27. CFTR modulator therapy in patients with cystic fibrosis and an organ transplant.
Mitchell RM; Jones AM; Barry PJ
Paediatr Respir Rev; 2018 Jun; 27():6-8. PubMed ID: 30158080
[TBL] [Abstract][Full Text] [Related]
28. The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series.
Ragan H; Autry E; Bomersback T; Hewlett J; Kormelink L; Safirstein J; Shanley L; Lubsch L
Pediatr Pulmonol; 2022 Feb; 57(2):411-417. PubMed ID: 34850610
[TBL] [Abstract][Full Text] [Related]
29. Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease.
Burgel PR; Paillasseur JL; Durieu I; Reynaud-Gaubert M; Hamidfar R; Murris-Espin M; Danner-Boucher I; Chiron R; Leroy S; Douvry B; Grenet D; Mely L; Ramel S; Montcouquiol S; Burnet E; Ouaalaya EH; Sogni P; Da Silva J; Martin C;
Ann Am Thorac Soc; 2024 Jul; 21(7):1053-1064. PubMed ID: 38579175
[No Abstract] [Full Text] [Related]
30. Highly effective cystic fibrosis transmembrane conductance (regulator) modulator therapy: shifting the curve for most while leaving some further behind.
Chun SW; Somers ME; Burgener EB
Curr Opin Pediatr; 2024 Jun; 36(3):290-295. PubMed ID: 38411576
[TBL] [Abstract][Full Text] [Related]
31. Peripheral lung effect of elexacaftor/tezacaftor/ivacaftor in adult cystic fibrosis.
Stylemans D; Darquenne C; Schuermans D; Verbanck S; Vanderhelst E
J Cyst Fibros; 2022 Jan; 21(1):160-163. PubMed ID: 33832855
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Elexacaftor-Tezacaftor-Ivacaftor on chronic rhinosinusitis in cystic fibrosis.
Di Gioia S; Lucca F; Venditto L; Sandri G; Tommasi N; Cipolli M; Molteni G
Am J Otolaryngol; 2024; 45(3):104236. PubMed ID: 38417261
[TBL] [Abstract][Full Text] [Related]
33. Cystic fibrosis transmembrane conductance receptor modulator therapy in cystic fibrosis, an update.
Egan ME
Curr Opin Pediatr; 2020 Jun; 32(3):384-388. PubMed ID: 32374578
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype.
Carnovale V; Iacotucci P; Terlizzi V; Colangelo C; Medio P; Ferrillo L; De Gregorio F; Francalanci M; Taccetti G; Buonaurio S; d'Ippolito M; Marsicovetere G; D'Andria M; Ferrara N; Salvatore D
Respir Med; 2021; 189():106646. PubMed ID: 34673344
[TBL] [Abstract][Full Text] [Related]
35. Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis.
Furstova E; Dousova T; Beranek J; Libik M; Fila L; Modrak M; Cinek O; Macek M; Drevinek P
J Cyst Fibros; 2022 Mar; 21(2):243-245. PubMed ID: 34348870
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access.
Hong E; Zampoli M; Beringer PM
Clin Pharmacol Ther; 2024 Jun; 115(6):1204-1207. PubMed ID: 38385853
[No Abstract] [Full Text] [Related]
38. Use of elexacaftor/tezacaftor/ivacaftor in liver transplant patients with cystic fibrosis.
McKinzie CJ; Doligalski CT; Lobritto SJ; Coakley RD; Gower WA
J Cyst Fibros; 2022 Mar; 21(2):227-229. PubMed ID: 34384711
[No Abstract] [Full Text] [Related]
39. Elexacaftor/Ivacaftor/Tezacaftor: First Approval.
Hoy SM
Drugs; 2019 Dec; 79(18):2001-2007. PubMed ID: 31784874
[TBL] [Abstract][Full Text] [Related]
40. A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation.
McKone EF; DiMango EA; Sutharsan S; Barto TL; Campbell D; Ahluwalia N; Higgins M; Owen CA; Tullis E
J Cyst Fibros; 2021 Mar; 20(2):234-242. PubMed ID: 33339768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
